We are contrasting Arcus Biosciences Inc. (NYSE:RCUS) and INSYS Therapeutics Inc. (NASDAQ:INSY) on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences Inc.	8.04M	59.43	50.51M	-1.18	0.00
INSYS Therapeutics Inc.	97.21M	3.65	125.32M	-1.60	0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Arcus Biosciences Inc. and INSYS Therapeutics Inc.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Arcus Biosciences Inc. and INSYS Therapeutics Inc.

	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences Inc.	-628.23%	0%	0%
INSYS Therapeutics Inc.	-128.92%	-362%	-50.8%

Liquidity

The Current Ratio and Quick Ratio of Arcus Biosciences Inc. are 16 and 16 respectively. Its competitor INSYS Therapeutics Inc.’s Current Ratio is 0.7 and its Quick Ratio is 0.6. Arcus Biosciences Inc. can pay off short and long-term obligations better than INSYS Therapeutics Inc.

Analyst Ratings

Arcus Biosciences Inc. and INSYS Therapeutics Inc. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Arcus Biosciences Inc.	0	0	0	0.00
INSYS Therapeutics Inc.	0	0	2	3.00

On the other hand, INSYS Therapeutics Inc.’s potential upside is 130.13% and its consensus target price is $11.

Institutional and Insider Ownership

The shares of both Arcus Biosciences Inc. and INSYS Therapeutics Inc. are owned by institutional investors at 40% and 22.2% respectively. Arcus Biosciences Inc.’s share held by insiders are 0.9%. On the other hand, insiders held about 63.83% of INSYS Therapeutics Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Arcus Biosciences Inc.	10.68%	12.26%	-2.69%	-21.59%	0%	-25.65%
INSYS Therapeutics Inc.	-14.48%	-36.93%	-36.54%	-26.15%	-12.29%	-46.57%

For the past year Arcus Biosciences Inc.’s stock price has smaller decline than INSYS Therapeutics Inc.

Summary

On 7 of the 11 factors Arcus Biosciences Inc. beats INSYS Therapeutics Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.